In the UK, different GLP-1 receptor agonists have specific licensed indications: For type 2 diabetes : semaglutide (Ozempic), dulaglutide (Trulicity), and liraglutide (Victoza) For weight management : semaglutide 2.4mg (Wegovy) and liraglutide 3.0mg (Saxenda) NICE guideline NG28 recommends GLP-1 receptor agonists as treatment options for type 2 diabetes when first-line therapies have not achieved adequate glycaemic control
The researchers were focused on diabetes (not obesity) treatment, and I have not included their calculations of the cost of gaining approval for biosimilars
This is a laboratory procedure, not instructions for administration to humans
If you do not have sufficient glutathione or you have a glutathione deficiency, this can leave you vulnerable to a wide range of diseases and health concerns
I have also changed my diet to only healthy foods, and started exercising regularly, so I can maintain this weight once I go to a lower, maintenance dose
However, semaglutide pens display doses in milligrams (mg), not units